Schonfeld Strategic Advisors’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARCT
AIM
NAMA
Schonfeld Strategic Advisors's ARCT Position: Q2 2026 in Review
Schonfeld Strategic Advisors opened a new position in Arcturus Therapeutics (ARCT) in Q2 2026: 26,315 shares worth $177K. The stake represents ﹤0.01% of the portfolio and ranks #2217 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in ARCT as recently as Q4 2025.
Schonfeld Strategic Advisors first reported a position in ARCT in Q2 2020 and has held it in 21 quarters since. The position peaked at $14.4M in Q4 2024. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.
- Schonfeld Strategic Advisors held 26,315 shares of Arcturus Therapeutics worth $177K as of Q2 2026.
- Arcturus Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
- Arcturus Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2217 holding.
- Schonfeld Strategic Advisors first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 21 quarters since.
- Schonfeld Strategic Advisors's Arcturus Therapeutics position peaked at $14.4M in Q4 2024.
- 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.